Helen Torley , , M.B. Ch. B., M.R.C.P. , , President, Chief Executive Officer and member of the Board of Directors

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).

Athena Countouriotis , , M.D. , , Senior Vice President & Chief Medical Officer

Dr. Countouriotis joined Halozyme in January 2015 as Senior Vice President, Chief Medical Officer. Dr. Countouriotis has participated in or led the clinical development and approvals of three oncology assets (Bosulif®, Sutent®, and Sprycel®). Most recently, Dr. Countouriotis served as Chief Medical Officer at Ambit Biosciences (acquired by Daiichi Sankyo in November 2014) where she was responsible for clinical development, and regulatory affairs. In this capacity, Dr. Countouriotis provided leadership to the development and clinical operations strategies for quizartinib, currently in Phase 3 development for Acute Myeloid Leukemia, and served as a key contributor to the successful initial public offering in May 2013. Prior to her role at Ambit Biosciences, Dr. Countouriotis served as global clinical leader for the Oncology Business Unit of Pfizer Inc. In this role, she led late-stage clinical development and the approvals for Bosulif in Chronic Myelogenous Leukemia. In addition, Athena was a clinical leader for Sutent, participating in a successful U.S. Food and Drug Administration advisory committee meeting leading to the approval of Sutent in pancreatic neuroendocrine tumors. Dr. Countouriotis received her M.D. from Tufts University School of Medicine and her bachelor’s degree from the University of California, Los Angeles. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training in the pediatric hematology/oncology program at the Fred Hutchinson Cancer Research Center.

William J. Fallon , , , Vice President, CMC Operations

Mr. William Fallon joined Halozyme in 2006 as Vice President, Manufacturing & Operations. His responsibilities include oversight of all aspects of internal and external manufacturing and facilities operations, as well as bioprocess development. Prior to Halozyme, he served as President and Chief Executive Officer of Cytovance Biologics, a contract manufacturing organization that provides manufacturing and development services to the biotechnology industry. From 2001 to 2003, he was Vice President of Technical Operations at Genzyme Corporation, having held the same position at Novazyme Pharmaceuticals, Inc. prior to its acquisition by Genzyme in 2001. Mr. Fallon joined Novazyme from Transkaryotic Therapies, where he was Vice President of Manufacturing from 1998 to 2001. From 1993 to 1998, he was employed in several management positions for the Ares-Serono Group, including Vice President, U.S. Manufacturing Operations. In this role, he served as general manager, overseeing the production and distribution of all of Serono's approved biotechnology products in the U.S. From 1990 to 1992, he was Director of Manufacturing for Centocor, Inc. His prior experience also includes various management and operational roles at Invitron Corporation and Travenol-Genentech Diagnostics. Mr. Fallon earned a B.S. in marine science and a B.A. in biology from Long Island University, and an M.S. in biology from Northeastern University.

Mark J. Gergen , , , Chief Operating Officer

Mr. Gergen joined Halozyme in September 2016 in a new role reporting to the CEO as Senior Vice President and Chief Operating Officer. He is responsible for business development, including the management of Halozyme’s proprietary ENHANZE™ platform collaborations and overseeing the global product teams responsible for planning the development and commercialization of Halozyme’s oncology pipeline, including clinical operations and clinical collaborations.

He brings more than 20 years of executive management and business development experience to Halozyme, with an extensive background in the biotechnology sector. Prior to joining Halozyme, he most recently served as Executive Vice President and Chief Operating Officer for Mirati Therapeutics, an oncology biotech company, responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions where he executed multiple successful partnerships, collaborations and licensing agreements.

Before Mirati, he was Senior Vice President of Corporate Development for Amylin Pharmaceuticals, leading business development and alliances. Earlier in his career, he held senior management roles at Cardionet and Advanced Tissue Sciences, as well as the large group purchasing organization, Premier, and medical device pioneer, Medtronic.

He earned his B.A. in Business Administration from Minot State University in North Dakota and J.D. from the University of Minnesota Law School.

Michael J. LaBarre , , Ph.D. , , Vice President, Chief Scientific Officer

Dr. Michael J. LaBarre has been with Halozyme since 2008 and oversees the research and development of early pipeline assets, product development, and Halozyme’s ENHANZE platform partnerships. Dr. LaBarre brings strong expertise in chemistry, manufacturing and controls (CMC) along with over 23-years of experience across all aspects of biopharmaceutical research and development. In his previous role as Vice President of Product Development at Paramount BioSciences, LLC, Dr. LaBarre led the CMC efforts for all of the product development programs within Paramount’s portfolio companies. Prior to joining Paramount, Dr. LaBarre served in various research and development positions from 1995 to 2006 at Biogen Idec (IDEC from 1995 to 2004), where he had responsibility for analytical and formulation development, protein purification, and physicochemical/biochemical characterization supporting numerous IND and BLA submissions, including those for the commercial products RITUXAN® and ZEVALIN®. His last position with Biogen Idec was Director of Analytical and Protein Biochemistry within the Discovery Research group. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the analytical methods development group and he began his career at Hybritech in San Diego, where he held positions in regulatory affairs and manufacturing technical support, focusing on conjugated/radiolabeled antibody technologies and analytical chemistry. Dr. LaBarre received his B.S. in chemistry from Southampton College of Long Island University and his Ph.D. in bioinorganic chemistry from the University of Arizona.

Harry J. Leonhardt , , Esq. , , Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Mr. Leonhardt joined Halozyme in April 2015 as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary. At Halozyme, he is responsible for all legal, compliance and intellectual property matters. Mr. Leonhardt brings more than 30 years of executive management, corporate legal, intellectual property, compliance, business development and mergers and acquisitions experience to Halozyme, with an extensive background in the biotechnology sector. Most recently, he served as Senior Vice President, Legal and Compliance, and Corporate Secretary at Amylin Pharmaceuticals, Inc., a biotech company (acquired by Bristol Myers Squibb in September 2012). Prior to Amylin, he served as Senior Vice President, General Counsel and Corporate Secretary at Senomyx, Inc., Executive Vice President, General Counsel and Corporate Secretary at Genoptix, Inc., and Senior Vice President, General Counsel and Corporate Secretary at Nanogen, Inc. Prior to Nanogen, Mr. Leonhardt held positions of increasing responsibility at Allergan, Inc. including Chief Litigation Counsel and General Counsel for European Operations. Early in his career, he was an attorney at Lyon & Lyon where he represented a number of prominent clients in the biotech, pharmaceutical and consumer products areas. Mr. Leonhardt received a B. Sc. In Pharmacy from the University of the Sciences in Philadelphia and a Juris Doctorate from USC Law School.

Jim S. Mazzola , , , Vice President, Corporate Communication and Investor Relations

Mr. Mazzola brings 25 years of public relations, financial communication and marketing communication experience to Halozyme. Mr. Mazzola joined Halozyme in March 2015 as Vice President, Corporate Communication and Investor Relations. From 2008 until 2015 he was Senior Vice President of Global Marketing, Communication and Investor Relations for CareFusion, and was responsible for the company's integrated marketing, communication and brand strategy, investor relations, sales operations and served as president of the CareFusion Foundation. Prior to joining CareFusion, he was Senior Vice President of Global Communication at Cardinal Health from 2003 until 2008 where he led corporate public relations, financial communication and the Cardinal Health Foundation. While at Dell from 1998 until 2003, he held roles of increasing responsibility, including managing all product communication and supporting communication programs for the CEO. He began his career at NCR Corp., and earned his BA in Communication and MBA from the University of Dayton.

Michael E. Paolucci , , , Vice President and Chief Human Resources Officer

Mr. Paolucci joined Halozyme in July 2015 as Vice President and Chief Human Resources Officer, where he is responsible for all aspects of the Company’s human capital strategies, programs, and policies. He brings deep experience as a senior advisor for executive management and Boards of dynamic and fast growing companies. He is also known for developing human capital strategies that are aligned with increasing sustainable shareholder value.

Prior to Halozyme, Mr. Paolucci served as the Executive Vice President, Chief Human Resources Officer for CareFusion. In this role, he was responsible for initiatives to attract, develop and retain employees, company-wide human resource strategy and programs that resulted in sustained improvements in business performance.

Before CareFusion, he served as Executive Vice President of Human Resources at NuVasive, and also spent five years at Life Technologies where he was responsible for global compensation, benefits and HCM systems. He was also head of Human Resources for the services division of Hewlett Packard and served in several leadership roles with EDS, which was acquired by Hewlett Packard. Prior to HP/EDS, he was a partner with the HR consulting firm Towers Perrin. Mr. Paolucci earned his bachelor’s degree in Finance from The Ohio State University.

Kenneth A. Schultz , , M.D. , , Vice President of Innovation, Strategy and Business Development

Kenneth A. Schultz, M.D., joined Halozyme in January 2015 as Vice President of Innovation, Strategy and Business Development. From 2013-2014, Dr. Schultz held roles of increasing responsibility with Medtronic Diabetes, where he most recently served as Chief of Staff, Strategy, and Business Development and was responsible for identifying and evaluating novel therapies to purchase, entering the type 2 diabetes market, pursuing comprehensive partnerships, creating new service line strategies, and pursuing external investments. Prior to his role at Medtronic Diabetes, Dr. Schultz worked at McKinsey & Company from 2007-2012, where he provided consultative services to a range of global organizations across the medical device and pharmaceutical sectors. Dr. Schultz received his medical degree from Texas Tech University, an MBA from IMD in Switzerland and a bachelor’s degree from the Texas A&M University. Dr. Schultz began his career as a practicing physician. From 1999-2005, he worked in various positions including Vice-Chairman of Emergency Medicine with EMCare Physicians.

Laurie D. Stelzer , , , Senior Vice President & Chief Financial Officer

Ms. Stelzer joined Halozyme in June 2015 as Senior Vice President, Chief Financial Officer. At Halozyme, she is responsible for the Finance, IT, and Hylenex Commercial organizations. Most recently, Ms. Stelzer served as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc. Prior to that she was the Division CFO for the Regenerative Medicine Division and the Head of Investor Relations at Shire. Prior to Shire, Ms. Stelzer held positions of increasing responsibility for 15 years at Amgen, Inc. including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. Early in her career, she held various finance and accounting positions in the real estate and banking industries. Ms. Stelzer received her MBA from the Anderson School at the University of California, Los Angeles, and a Bachelor of Science in Accounting from Arizona State University.

Kristina Vlaovic , , , Vice President of Regulatory & Safety

Ms. Vlaovic joined Halozyme in 2015 as Vice President of Regulatory & Safety. Prior to her arrival at Halozyme, she was the global regulatory head for Genentech’s ophthalmology and respiratory franchises. Preceding her experience at Genentech, she has more than 15 years of industry experience at companies such as Amgen, InterMune and Pfizer, leading and implementing strategic regulatory paths for products such as Lucentis®, Enbrel®, Esbriet® and Sutent®, as well as development strategies for numerous Phase 1-3 molecules. Ms. Vlaovic received her BS and MPH from the University of Michigan.

Homa Yeganegi , , , Vice President, Global Scientific and Medical Affairs

Homa Yeganegi joined Halozyme in March 2016 as the Vice President of Global Scientific and Medical Affairs. Ms. Yeganegi has extensive experience in building and leading oncology focused Global Medical Affairs teams at Clovis Oncology Pharmaceuticals, Exelixis Pharmaceuticals and Onyx Pharmaceuticals. Most recently she was Vice President of Global Medical Affairs at Clovis Oncology Pharmaceuticals where she successfully supported the pre-launch activities for Rociletinib in non-small cell lung cancer in the US and EU. She has a demonstrated track record of success developing strategic data generation, opinion leader development and engagement, scientific strategy and communication including global medical information and scientific education. Ms. Yeganegi has a B. Sc. in biology from the University of Tehran, Iran and a Master of Science in Neuroanatomy from the University of Western Australia and is completing her Ph.D. in Health Sciences.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.